Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy
NCT07770815Phase 3Not yet recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 3 trial of sibeprenlimab in IgA nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Development & Commercialization. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07770815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770815.